Blood | 2025
Standard-of-care Idecabtagene Vicleucel for relapsed/refractory multiple myeloma: A CIBMTR analysis.
Sidana S, Ahmed N, Akhtar OS, Brazauskas R, Oloyede T, Bye M, Hansen DK, Ferreri CJ, Freeman CL, Afrough A, Anderson LD Jr., Dhakal B, Dhanda DS, Gowda L, Hashmi H, Harrison MJ, Kitali A, Landau HJ, Mirza AS, Patwardhan P, Qazilbash MH, Usmani SZ, Patel KK, Nishihori T, Ganguly S, Pasquini MC
PubMed
PMID: 40198886
Abstract
Related Articles
CIBMTR Study #: MM23-01a